Market research
IMVT Immunovant Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9B
- P/E ratio
- Not available
- Analyst target
- 48.875
- Dividend yield
- Not available
- Beta
- 0.81
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45258J1025
- Market cap
- 9B
- P/E ratio
- Not available
- Analyst target
- 48.875
- Dividend yield
- Not available
- Beta
- 0.81
About
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IMVT discussion.
5 years, 4 months ago
Immunovant, Inc is currently in a long term downtrend where the price is trading 62.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Immunovant, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 181.3% to $-32M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.3% to $-23M since the same quarter in the previous year.
Based on the above factors, Immunovant, Inc gets an overall score of 2/5.